HOUSTON, March 21, 2008 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) previously reported the filing of its annual report on Form 10-K for the year ended December 31, 2007. This filing is available for review on Encysive's website at www.encysive.com or on the Securities and Exchange Commission's website at www.sec.gov.
As required under Nasdaq Marketplace Rule 4350(b)(1)(B), Encysive today announced that its independent auditor's report included in the annual report on Form 10-K contains a statement relating to their substantial doubt about Encysive's ability to continue as a going concern.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: www.encysive.com.
The Encysive Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=843